(-)-demecolcine increases expression EXP 6480464 Demecolcine results in increased expression of H2BC5 mRNA CTD PMID:23649840 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane decreases expression EXP 6480464 o, p'-DDT results in decreased expression of H2BC5 mRNA CTD PMID:19371625 1,2-dimethylhydrazine multiple interactions ISO RGD:1316136 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of H2BC14 mRNA CTD PMID:22206623 17beta-estradiol multiple interactions EXP 6480464 [Progesterone co-treated with Estradiol] results in increased expression of H2BC5 mRNA CTD PMID:17404688 17beta-estradiol affects expression EXP 6480464 Estradiol affects the expression of H2BC5 mRNA CTD PMID:22574217 17beta-estradiol decreases expression EXP 6480464 Estradiol results in decreased expression of H2BC5 mRNA CTD PMID:23019147 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of H2BC5 mRNA CTD PMID:17101203 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1316136 6480464 Tetrachlorodibenzodioxin affects the expression of H2BC14 mRNA CTD PMID:21570461 , PMID:24680724 2-hydroxypropanoic acid decreases expression EXP 6480464 Lactic Acid results in decreased expression of H2BC5 mRNA CTD PMID:30851411 2-methylcholine affects expression EXP 6480464 beta-methylcholine affects the expression of H2BC5 mRNA CTD PMID:21179406 3-isobutyl-1-methyl-7H-xanthine multiple interactions EXP 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of H2BC5 mRNA CTD PMID:28628672 4-\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\}benzoic acid decreases expression EXP 6480464 Am 580 results in decreased expression of H2BC5 mRNA CTD PMID:16982809 4-hydroxyphenyl retinamide decreases expression ISO RGD:1316136 6480464 Fenretinide results in decreased expression of H2BC10 mRNA CTD PMID:28973697 5-aza-2'-deoxycytidine affects expression EXP 6480464 Decitabine affects the expression of H2BC5 mRNA CTD PMID:23300844 6-propyl-2-thiouracil decreases expression ISO RGD:1307126 6480464 Propylthiouracil results in decreased expression of HIST1H2BD mRNA CTD PMID:24780913 , PMID:25825206 acetamide increases expression ISO RGD:1307126 6480464 acetamide results in increased expression of HIST1H2BD mRNA CTD PMID:31881176 aflatoxin B1 decreases methylation EXP 6480464 Aflatoxin B1 results in decreased methylation of H2BC5 gene CTD PMID:27153756 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of H2BC5 mRNA CTD PMID:27153756 all-trans-retinoic acid decreases expression EXP 6480464 Tretinoin results in decreased expression of H2BC5 mRNA CTD PMID:21934132 Aroclor 1254 increases expression ISO RGD:1316136 6480464 Chlorodiphenyl 54% Chlorine results in increased expression of H2BC14 mRNA CTD PMID:23650126 arsenous acid decreases expression EXP 6480464 Arsenic Trioxide results in decreased expression of H2BC5 mRNA CTD PMID:25555879 , PMID:26705709 arsenous acid multiple interactions EXP 6480464 [Arsenic Trioxide co-treated with Ascorbic Acid] results in decreased expression of H2BC5 mRNA CTD PMID:25555879 azathioprine increases expression EXP 6480464 Azathioprine results in increased expression of H2BC5 mRNA CTD PMID:22623647 belinostat decreases expression EXP 6480464 belinostat results in decreased expression of H2BC5 mRNA CTD PMID:26272509 belinostat multiple interactions EXP 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of H2BC5 mRNA CTD PMID:27188386 benzene decreases expression ISO RGD:1316136 6480464 Benzene results in decreased expression of H2BC14 mRNA CTD PMID:15120971 benzo[a]pyrene increases expression EXP 6480464 Benzoapyrene results in increased expression of H2BC5 mRNA CTD PMID:20064835 more ... benzo[a]pyrene increases expression ISO RGD:1316136 6480464 Benzoapyrene results in increased expression of H2BC14 mRNA CTD PMID:22610609 benzo[a]pyrene multiple interactions ISO RGD:1316136 6480464 [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of H2BC14 mRNA CTD PMID:27858113 benzo[a]pyrene diol epoxide I increases expression EXP 6480464 7 more ... CTD PMID:20382639 benzo[b]fluoranthene increases expression ISO RGD:1316136 6480464 benzobfluoranthene results in increased expression of H2BC14 mRNA CTD PMID:26377693 benzo[b]fluoranthene multiple interactions ISO RGD:1316136 6480464 [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of H2BC14 mRNA CTD PMID:27858113 berberine decreases expression EXP 6480464 Berberine results in decreased expression of H2BC5 mRNA CTD PMID:27311644 bis(2-chloroethyl) sulfide increases expression EXP 6480464 Mustard Gas results in increased expression of H2BC5 mRNA CTD PMID:25102026 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of H2BC5 mRNA CTD PMID:19371625 , PMID:29275510 bisphenol A increases expression ISO RGD:1307126 6480464 bisphenol A results in increased expression of HIST1H2BD mRNA CTD PMID:25181051 , PMID:30816183 bisphenol A increases methylation ISO RGD:1307126 6480464 bisphenol A results in increased methylation of HIST1H2BD gene CTD PMID:28505145 bisphenol A decreases expression ISO RGD:1307126 6480464 bisphenol A results in decreased expression of HIST1H2BD mRNA CTD PMID:25181051 bisphenol A multiple interactions EXP 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of H2BC5 mRNA CTD PMID:28628672 calcitriol multiple interactions EXP 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of H2BC5 mRNA CTD PMID:21592394 calcitriol increases expression EXP 6480464 Calcitriol results in increased expression of H2BC5 mRNA CTD PMID:21592394 carbon nanotube decreases expression ISO RGD:1316136 6480464 Nanotubes more ... CTD PMID:25554681 , PMID:25620056 chrysene multiple interactions ISO RGD:1316136 6480464 [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of H2BC14 mRNA CTD PMID:27858113 cisplatin affects expression EXP 6480464 Cisplatin affects the expression of H2BC5 mRNA CTD PMID:23300844 copper atom multiple interactions EXP 6480464 [NSC 689534 binds to Copper] which results in increased expression of H2BC5 mRNA CTD PMID:20971185 copper(0) multiple interactions EXP 6480464 [NSC 689534 binds to Copper] which results in increased expression of H2BC5 mRNA CTD PMID:20971185 copper(II) sulfate increases expression EXP 6480464 Copper Sulfate results in increased expression of H2BC5 mRNA CTD PMID:19549813 coumestrol decreases expression EXP 6480464 Coumestrol results in decreased expression of H2BC5 mRNA CTD PMID:19167446 coumestrol multiple interactions EXP 6480464 [Coumestrol co-treated with 2 more ... CTD PMID:19167446 crocidolite asbestos increases expression EXP 6480464 Asbestos, Crocidolite results in increased expression of H2BC5 mRNA CTD PMID:25351596 curcumin increases expression EXP 6480464 Curcumin results in increased expression of H2BC5 mRNA CTD PMID:17999991 cyclosporin A decreases expression EXP 6480464 Cyclosporine results in decreased expression of H2BC5 mRNA CTD PMID:20106945 , PMID:27989131 decabromodiphenyl ether affects expression EXP 6480464 decabromobiphenyl ether affects the expression of H2BC5 mRNA CTD PMID:24834073 deoxynivalenol increases expression EXP 6480464 deoxynivalenol results in increased expression of H2BC5 mRNA CTD PMID:31863870 dexamethasone multiple interactions EXP 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of H2BC5 mRNA CTD PMID:28628672 diarsenic trioxide multiple interactions EXP 6480464 [Arsenic Trioxide co-treated with Ascorbic Acid] results in decreased expression of H2BC5 mRNA CTD PMID:25555879 diarsenic trioxide decreases expression EXP 6480464 Arsenic Trioxide results in decreased expression of H2BC5 mRNA CTD PMID:25555879 , PMID:26705709 dibenz[a,h]anthracene increases expression ISO RGD:1316136 6480464 1 more ... CTD PMID:26377693 dichloroacetic acid increases expression ISO RGD:1316136 6480464 Dichloroacetic Acid results in increased expression of H2BC14 mRNA CTD PMID:28962523 dorsomorphin multiple interactions EXP 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 doxorubicin decreases expression EXP 6480464 Doxorubicin results in decreased expression of H2BC5 mRNA CTD PMID:29803840 Enterolactone multiple interactions EXP 6480464 [Coumestrol co-treated with 2, 3-bis3'-hydroxybenzylbutyrolactone] results in decreased expression of H2BC5 mRNA CTD PMID:19167446 entinostat multiple interactions EXP 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of H2BC5 mRNA CTD PMID:27188386 entinostat decreases expression EXP 6480464 entinostat results in decreased expression of H2BC5 mRNA CTD PMID:26272509 ferric oxide decreases expression ISO RGD:1316136 6480464 ferric oxide analog results in decreased expression of H2BC14 mRNA CTD PMID:25086211 folic acid multiple interactions ISO RGD:1316136 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of H2BC14 mRNA CTD PMID:22206623 formaldehyde increases expression EXP 6480464 Formaldehyde results in increased expression of H2BC5 mRNA CTD PMID:23649840 genistein decreases expression EXP 6480464 Genistein results in decreased expression of H2BC5 mRNA CTD PMID:19371625 hydrogen peroxide affects expression EXP 6480464 Hydrogen Peroxide affects the expression of H2BC5 mRNA CTD PMID:21179406 indometacin multiple interactions EXP 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of H2BC5 mRNA CTD PMID:28628672 isotretinoin decreases expression EXP 6480464 Isotretinoin results in decreased expression of H2BC5 mRNA CTD PMID:20436886 L-ascorbic acid multiple interactions EXP 6480464 [Arsenic Trioxide co-treated with Ascorbic Acid] results in decreased expression of H2BC5 mRNA CTD PMID:25555879 mercury dibromide decreases expression EXP 6480464 mercuric bromide results in decreased expression of H2BC5 mRNA CTD PMID:26272509 mercury dibromide multiple interactions EXP 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of H2BC5 mRNA CTD PMID:27188386 methyl methacrylate increases expression ISO RGD:1316136 6480464 Methylmethacrylate results in increased expression of H2BC14 mRNA CTD PMID:16916219 methyl methanesulfonate increases expression EXP 6480464 Methyl Methanesulfonate results in increased expression of H2BC5 mRNA CTD PMID:23649840 methylisothiazolinone increases expression EXP 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of H2BC5 mRNA CTD PMID:31629900 methylparaben increases expression EXP 6480464 methylparaben results in increased expression of H2BC5 mRNA CTD PMID:31745603 N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine increases expression EXP 6480464 N more ... CTD PMID:19013360 p-chloromercuribenzoic acid decreases expression EXP 6480464 p-Chloromercuribenzoic Acid results in decreased expression of H2BC5 mRNA CTD PMID:26272509 p-chloromercuribenzoic acid multiple interactions EXP 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of H2BC5 mRNA CTD PMID:27188386 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of H2BC5 mRNA CTD PMID:21420995 pirinixic acid increases expression ISO RGD:1316136 6480464 pirinixic acid results in increased expression of H2BC14 mRNA CTD PMID:23811191 progesterone multiple interactions EXP 6480464 [Progesterone co-treated with Estradiol] results in increased expression of H2BC5 mRNA CTD PMID:17404688 propionic acid decreases expression EXP 6480464 propionic acid results in decreased expression of H2BC5 mRNA CTD PMID:31526819 quercetin increases expression EXP 6480464 Quercetin results in increased expression of H2BC5 mRNA CTD PMID:21632981 rac-lactic acid decreases expression EXP 6480464 Lactic Acid results in decreased expression of H2BC5 mRNA CTD PMID:30851411 resveratrol decreases expression EXP 6480464 Resveratrol results in decreased expression of H2BC5 mRNA CTD PMID:19371625 resveratrol multiple interactions EXP 6480464 [Coumestrol co-treated with Resveratrol] results in decreased expression of H2BC5 mRNA CTD PMID:19167446 SB 431542 multiple interactions EXP 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 silicon dioxide increases expression EXP 6480464 Silicon Dioxide analog results in increased expression of H2BC5 mRNA, Silicon Dioxide results in increased expression of H2BC5 mRNA CTD PMID:23806026 , PMID:25351596 sodium arsenite decreases expression EXP 6480464 sodium arsenite results in decreased expression of H2BC5 mRNA CTD PMID:24516582 sunitinib decreases expression EXP 6480464 Sunitinib results in decreased expression of H2BC5 mRNA CTD PMID:31533062 T-2 toxin increases expression EXP 6480464 T-2 Toxin results in increased expression of H2BC5 mRNA CTD PMID:31863870 tert-butyl hydroperoxide increases expression EXP 6480464 tert-Butylhydroperoxide results in increased expression of H2BC5 mRNA CTD PMID:15336504 testosterone multiple interactions EXP 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of H2BC5 mRNA CTD PMID:21592394 testosterone increases expression EXP 6480464 Testosterone results in increased expression of H2BC5 mRNA CTD PMID:21592394 tetraphene multiple interactions ISO RGD:1316136 6480464 [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of H2BC14 mRNA CTD PMID:27858113 trichostatin A decreases expression EXP 6480464 trichostatin A results in decreased expression of H2BC5 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions EXP 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of H2BC5 mRNA CTD PMID:27188386 troglitazone increases expression EXP 6480464 Troglitazone results in increased expression of H2BC5 mRNA CTD PMID:19140230 urethane increases expression EXP 6480464 Urethane results in increased expression of H2BC5 mRNA CTD PMID:28818685 valproic acid decreases expression EXP 6480464 Valproic Acid results in decreased expression of H2BC5 mRNA CTD PMID:24383497 more ... valproic acid increases expression EXP 6480464 Valproic Acid results in increased expression of H2BC5 mRNA CTD PMID:28001369 valproic acid affects expression EXP 6480464 Valproic Acid affects the expression of H2BC5 mRNA CTD PMID:25979313 vincristine increases expression EXP 6480464 Vincristine results in increased expression of H2BC5 mRNA CTD PMID:23649840 zearalenone decreases expression EXP 6480464 Zearalenone results in decreased expression of H2BC5 mRNA CTD PMID:19371625 zoledronic acid increases expression EXP 6480464 Zoledronic Acid results in increased expression of H2BC5 mRNA CTD PMID:24714768 
